← Leaderboards
William Schiemann
Case Western Reserve University
$12,636,493
Attributed
$17,622,434
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,622,434 · 12
By mechanism
R01$16,800,660 · 9
P30$821,774 · 3
Top collaborators
- Zheng-Rong Lu7 shared
- Efstathios Karathanasis5 shared
- Saba Valadkhan5 shared
- Alex Yee-Chen Huang2 shared
- Xiaofeng Zhu2 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Zheng-Rong Lu$13,267,567
- Saba Valadkhan$3,043,119
- Nathan A. Berger$11,283,519
- Vinay Varadan$1,742,087
- Alex Yee-Chen Huang$8,501,439
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorNeoplasm MetastasisCellsMediatingResponseEventMolecularUnited StatesWomanProteinsChemotherapyTriple-Negative Invasive Breast CarcinomaMalignant Breast NeoplasmMalignant NeoplasmsBaseOncogenicPreventSignal TransductionIn VivoCessation Of LifeComplexComprehensive Cancer CenterMedicineCharacteristics
Grant awards (51)
MIZ1 Activation in Triple-negative Breast Cancer Racial Disparities$617,723
R01 · FY2025 · CA · contact PI
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy$405,115
R01 · FY2025 · CA
MIZ1 Activation in Triple-negative Breast Cancer Racial Disparities$617,723
R01 · FY2024 · CA · contact PI
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis$561,099
R01 · FY2024 · CA
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy$405,116
R01 · FY2024 · CA
Athymic Animal and Preclinical Therapeutics Shared Resource$184,767
P30 · FY2024 · CA · contact PI
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis$578,041
R01 · FY2023 · CA
Role of the lncRNA BORG in Breast Cancer Metastatic Progression and Recurrence$447,306
R01 · FY2023 · CA · contact PI
Athymic Animal and Preclinical Therapeutics Shared Resource$184,767
P30 · FY2023 · CA · contact PI
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis$578,640
R01 · FY2022 · CA
Role of the lncRNA BORG in Breast Cancer Metastatic Progression and Recurrence$447,306
R01 · FY2022 · CA · contact PI
Athymic Animal and Preclinical Therapeutics Shared Resource$151,577
P30 · FY2022 · CA · contact PI
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis$591,126
R01 · FY2021 · CA
Role of the lncRNA BORG in Breast Cancer Metastatic Progression and Recurrence$456,435
R01 · FY2021 · CA · contact PI
Athymic Animal and Preclinical Therapeutics Shared Resource$150,828
P30 · FY2021 · CA · contact PI
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis$591,007
R01 · FY2020 · CA
Role of the lncRNA BORG in Breast Cancer Metastatic Progression and Recurrence$454,781
R01 · FY2020 · CA · contact PI
Athymic Animal and Preclinical Therapeutics Shared Resource$149,835
P30 · FY2020 · CA · contact PI
Image-guided EMT inhibition for treating metastatic breast cancer$459,637
R01 · FY2019 · CA
Role of the lncRNA BORG in Breast Cancer Metastatic Progression and Recurrence$453,600
R01 · FY2019 · CA · contact PI
Image-guided EMT inhibition for treating metastatic breast cancer$473,853
R01 · FY2018 · CA
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis$75,000
R01 · FY2018 · CA · contact PI
Image-guided EMT inhibition for treating metastatic breast cancer$473,853
R01 · FY2017 · CA
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis$328,265
R01 · FY2017 · CA · contact PI
Image-guided EMT inhibition for treating metastatic breast cancer$473,853
R01 · FY2016 · CA
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis$328,265
R01 · FY2016 · CA · contact PI
Integrin-mediated Regulation of TGFbeta Signaling and Tumorigenesis$289,351
R01 · FY2016 · CA · contact PI
Image-guided EMT inhibition for treating metastatic breast cancer$473,853
R01 · FY2015 · CA
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis$328,265
R01 · FY2015 · CA · contact PI
Integrin-mediated Regulation of TGFbeta Signaling and Tumorigenesis$289,351
R01 · FY2015 · CA · contact PI
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis$318,418
R01 · FY2014 · CA · contact PI
Integrin-mediated Regulation of TGFbeta Signaling and Tumorigenesis$280,670
R01 · FY2014 · CA · contact PI
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis$342,360
R01 · FY2013 · CA · contact PI
Integrin-mediated Regulation of TGFbeta Signaling and Tumorigenesis$271,990
R01 · FY2013 · CA · contact PI
Integrin-mediated Regulation of TGFbeta Signaling and Tumorigenesis$289,351
R01 · FY2012 · CA · contact PI
Integrin-Mediated Regulation of TGF-Beta Signaling and Tumorigenesis$289,351
R01 · FY2011 · CA · contact PI
Integrin-Mediated Regulation of TGF-Beta Signaling and Tumorigenesis$298,300
R01 · FY2010 · CA · contact PI
Integrin-Mediated Regulation of TGF-Beta Signaling and Tumorigenesis$292,600
R01 · FY2009 · CA · contact PI
Use of Cystatin C to Combat TGF-Beta Tumorigenesis$255,743
R01 · FY2009 · CA · contact PI
Integrin-Mediated Regulation of TGF-Beta Signaling and Tumorigenesis$292,600
R01 · FY2008 · CA · contact PI
Use of Cystatin C to Combat TGF-Beta Tumorigenesis$255,871
R01 · FY2008 · CA · contact PI
Integrin-Mediated Regulation of TGF-Beta Signaling and Tumorigenesis$292,600
R01 · FY2007 · CA · contact PI
Use of Cystatin C to Combat TGF-Beta Tumorigenesis$255,996
R01 · FY2007 · CA · contact PI
Role of Fibulin-5 in Tumorigenesis and TGF-beta Biology$253,012
R01 · FY2007 · CA · contact PI
Use of Cystatin C to Combat TGF-Beta Tumorigenesis$270,774
R01 · FY2006 · CA · contact PI
Role of Fibulin-5 in Tumorigenesis and TGF-beta Biology$142,103
R01 · FY2006 · CA · contact PI
Role of Fibulin-5 in Tumorigenesis and TGF-beta Biology$121,404
R01 · FY2006 · CA · contact PI
Use of Cystatin C to Combat TGF-Beta Tumorigenesis$274,250
R01 · FY2005 · CA
Role of Fibulin-5 in Tumorigenesis and TGF-beta Biology$269,848
R01 · FY2005 · CA
Role of Fibulin-5 in Tumorigenesis and TGF-beta Biology$269,848
R01 · FY2004 · CA
Role of Fibulin-5 in Tumorigenesis and TGF-beta Biology$265,007
R01 · FY2003 · CA